sarpogrelate has been researched along with Diseases, Peripheral Vascular in 4 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Indices of insulin resistance (IR) (fasting immunoreactive insulin (IRI) and calculated homeostasis model assessment (HOMA-R)) and adiponectin were measured before and after 2 weeks of sarpogrelate administration (300 mg/day) in 24 patients (19 men, 76+/-9 years) with PAD." | 5.12 | Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. ( Eguchi, M; Hase, M; Hashimoto, A; Kokubu, N; Miura, T; Nagao, K; Nakata, T; Shimamoto, K; Tsuchihashi, K; Tsuzuki, M; Ura, N; Wakabayashi, C; Wakabayashi, T; Yuda, S, 2006) |
| " Forearm blood flow (FBF) and leg blood flow (LBF) responses to reactive hyperemia (RH) and sublingual administration of nitroglycerin (NTG) were measured using strain-gauge plethysmography." | 5.12 | Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. ( Chayama, K; Goto, C; Higashi, Y; Miyazaki, M; Orihashi, K; Sanada, H; Sueda, T; Yoshizumi, M, 2007) |
| "Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells." | 2.80 | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results. ( Chen, YX; Gu, YQ; Hu, HJ; Li, XQ; Liu, CW; Song, XJ; Tian, HY; Wang, WD; Zhao, JC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YX | 1 |
| Wang, WD | 1 |
| Song, XJ | 1 |
| Gu, YQ | 1 |
| Tian, HY | 1 |
| Hu, HJ | 1 |
| Zhao, JC | 1 |
| Li, XQ | 1 |
| Liu, CW | 1 |
| Doggrell, SA | 1 |
| Kokubu, N | 1 |
| Tsuchihashi, K | 1 |
| Yuda, S | 1 |
| Hase, M | 1 |
| Eguchi, M | 1 |
| Wakabayashi, T | 1 |
| Hashimoto, A | 1 |
| Nakata, T | 1 |
| Miura, T | 1 |
| Ura, N | 1 |
| Nagao, K | 1 |
| Tsuzuki, M | 1 |
| Wakabayashi, C | 1 |
| Shimamoto, K | 1 |
| Miyazaki, M | 1 |
| Higashi, Y | 1 |
| Goto, C | 1 |
| Chayama, K | 1 |
| Yoshizumi, M | 1 |
| Sanada, H | 1 |
| Orihashi, K | 1 |
| Sueda, T | 1 |
1 review available for sarpogrelate and Diseases, Peripheral Vascular
| Article | Year |
|---|---|
The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.
Topics: Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Carrier Proteins; Coronary Circulat | 2003 |
3 trials available for sarpogrelate and Diseases, Peripheral Vascular
| Article | Year |
|---|---|
Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Female; Fibrinolytic Agents; Humans; Kaplan-Meier Es | 2015 |
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.
Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Blood Pressure; Female; Homeostasis; Humans; | 2006 |
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Arterial Occlusive Diseases; Biomarkers; Endothelium, | 2007 |